4 citations
,
November 2017 in “The Journal of Dermatology” Sorafenib may cause hair loss in a way similar to alopecia areata.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
9 citations
,
November 2004 in “Bioorganic & Medicinal Chemistry Letters” New compounds were made that effectively block enzymes related to prostate issues and hair loss.
July 2024 in “Journal of Investigative Dermatology” INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
September 2022 in “Plastic and Reconstructive Surgery” Baricitinib helps with severe hair loss, negative-pressure therapy lowers hernia recurrence, tranexamic acid reduces bleeding, robot-assisted breast surgery may improve outcomes, and acellular dermal matrix could decrease breast reconstruction complications.
34 citations
,
October 2021 in “Scientific Reports” Nobiletin-loaded vesicles effectively treat skin cancer by restoring normal miRNA and antioxidant levels.
1 citations
,
September 2024 in “International Journal of Advanced Multidisciplinary Research and Studies” Chemotherapy with carboplatin-paclitaxel causes hair loss in all patients.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
6 citations
,
June 2025 in “Nano Biomedicine and Engineering” Smart nano-PROTACs improve cancer treatment by targeting proteins more precisely and reducing side effects.
May 2026 in “Journal of Neurosciences in Rural Practice” Tofacitinib may cause nerve damage in the brain, so monitor for neurological symptoms.
September 2023 in “PubMed” Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
January 2025 in “International Journal of Dermatology” Tofacitinib improved hair and nail conditions in a teen with alopecia areata.
5 citations
,
January 2021 in “Dermatology Online Journal” An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.
3 citations
,
August 2020 in “Cutaneous and Ocular Toxicology” ATP helps prevent skin damage from vandetanib by reducing stress.
February 2006 in “PubMed” Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.
Inhibiting AP-1 changes skin tumor types and affects tumor cell identity.
February 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.
17 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
February 2006 in “Journal of The American Academy of Dermatology” Terbinafine is more effective than itraconazole for toenail fungus, especially in older patients, and debridement improves its effectiveness.
78 citations
,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
1 citations
,
March 2023 in “Medicine” The combination therapy is effective and well-tolerated for treating esophageal cancer.
148 citations
,
March 2022 in “The New England Journal of Medicine” Baricitinib was effective in treating alopecia areata in two major trials.
September 2024 in “Journal of the American Academy of Dermatology” Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.
5 citations
,
October 2023 in “Phytotherapy Research” Dauricine may help treat certain brain cancers by reducing cancer cell growth and promoting cell death.
22 citations
,
September 2014 in “Hormones” Metformin may help treat neuroendocrine tumors.
November 2025 in “Mendeley Data” JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.
December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.